Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sorbitol+Phenylephrine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Morphine High Dose |
| 2 | PLACEBO_COMPARATOR | Morphine Low Dose |
| 3 | PLACEBO_COMPARATOR | Sorbitol Phenylephrine |
| 4 | EXPERIMENTAL | Sorbitol high concentration+Phenylephrine+Morphine |
| 5 | EXPERIMENTAL | Sorbitol low concentration+Phenylephrine+Morphine |
| Name | Type | Description |
|---|---|---|
| Morphine | DRUG | Morphine |
| Sorbitol+Phenylephrine | DRUG | Sorbitol+Phenylephrine |
| Sorbitol+Phenylephrine+Morphine | DRUG | Sorbitol+Phenylephrine+Morphine |
| Sorbitol low concentration+Phenylephrine+Morphine | DRUG | Sorbitol low concentration+Phenylephrine+Morphine |
Inclusion Criteria: * Ability to provide written informed consent * Healthy male or female between 18 and 40 years of age, inclusive. * Women have to test negative for pregnancy. * Body weight within 15% of ideal body weight based on Metropolitan Life assurance tables. * No concomitant medications ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | N/A | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | - | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | - | Flozin |
Sorbitol+Phenylephrine is an investigational small molecule combination being studied for the treatment of acute pain. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being developed by BioLineRx Ltd. (NASDAQ: BLRX).
Sorbitol+Phenylephrine combines sorbitol, a sugar alcohol, with phenylephrine, a decongestant and vasoconstrictor. The combination is being studied for its potential to enhance the effects of morphine in managing acute pain. The exact mechanism of action for this combination in pain relief is under investigation.
Sorbitol+Phenylephrine is being developed by BioLineRx Ltd., a biopharmaceutical company traded on NASDAQ under the ticker symbol BLRX. The company is conducting clinical trials to evaluate the safety and efficacy of this combination therapy for acute pain.
Sorbitol+Phenylephrine is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for its safety and efficacy in treating acute pain, with one completed Phase 1 trial.
Sorbitol+Phenylephrine has one completed clinical trial registered under NCT00374881, titled "A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects." This Phase 1, randomized, double-blind, placebo-controlled study enrolled 9 healthy volunteers in Israel.
No, Sorbitol+Phenylephrine is a combination product that contains both sorbitol and phenylephrine. It is being studied in combination with morphine for acute pain. Phenylephrine alone is a decongestant, but the combination with sorbitol is being investigated for a different purpose in pain management.